Heterogeneity in renal cell carcinoma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Molecular characterization of renal cell carcinoma (RCC) has improved understanding of driver genes, pathways, and the tumor microenvironment.
• Advancements in molecular profiling have revolutionized metastatic RCC treatment, yet treatment resistance remains a significant challenge.
• Tumor heterogeneity is a primary driver of resistance and subsequent treatment failure in RCC.

Purpose of the Study:

• To review the literature on the mechanisms of tumor heterogeneity in renal cell carcinoma.
• To explore the clinical implications of tumor heterogeneity in RCC treatment resistance.

Main Methods:

• A comprehensive literature search was conducted using the MEDLINE/PubMed Index.

Main Results:

• Intertumor and intratumor heterogeneity contribute to treatment failure and resistance in RCC.
• Genetic profiles of renal tumors exhibit spatial differences within tumors and variations among patients.
• Genomic mutations can change over time, leading to the dominance of resistant subclones.

Conclusions:

• Improved tissue sampling is needed to account for intratumor and intertumor heterogeneity.
• Better understanding of heterogeneity will enhance the identification of driver mutations and actionable targets.
• Personalized treatment strategies based on individual molecular profiles are essential to move beyond one-size-fits-all approaches.